SCHEMBL4512882

SCHEMBL4512882

Cc1[nH]c(=O)c(C(=O)O)cc1C(=O)/C=C/c1cccc(OCC(=O)O)c1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYSLTR2 Q9NS75 6/20 0.52
ACMSD Q8TDX5 1/20 0.49
KDM4E B2RXH2 2/20 0.46
ALDH1A1 P00352 2/20 0.46
SMN1; SMN2 Q16637 1/20 0.46
CYSLTR1 Q9Y271 5/20 0.45
MAOA P21397 1/20 0.42
MAOB P27338 1/20 0.42
ABCG2 Q9UNQ0 1/20 0.42
LMNA P02545 2/20 0.42
MEN1 O00255 1/20 0.42
NR1I2 O75469 1/20 0.42
PGR P06401 1/20 0.42
ADRB2 P07550 1/20 0.42
ADRB1 P08588 1/20 0.42
ADORA3 P0DMS8 1/20 0.42
MAPT P10636 1/20 0.42
HPGD P15428 1/20 0.42
CNR1 P21554 1/20 0.42
TBXA2R P21731 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4512885 1.00 CYSLTR2 (0.52) CYSLTR2ACMSDKDM4EALDH1A1SMN1; SMN2
SCHEMBL4510052 0.85 CYSLTR2 (0.51) CYSLTR2ACMSDKDM4EALDH1A1SMN1; SMN2
SCHEMBL4512630 0.78 LMNA (0.58) CYSLTR2ACMSDKDM4EALDH1A1SMN1; SMN2
SCHEMBL4512637 0.78 LMNA (0.58) CYSLTR2ACMSDKDM4EALDH1A1SMN1; SMN2
SCHEMBL4515466 0.78 ACMSD (0.48) CYSLTR2ACMSDKDM4EALDH1A1SMN1; SMN2
SCHEMBL4515474 0.78 ACMSD (0.48) CYSLTR2ACMSDKDM4EALDH1A1SMN1; SMN2
SCHEMBL2278626 0.77 ACMSD (0.49) CYSLTR2ACMSDKDM4EALDH1A1SMN1; SMN2
SCHEMBL2278624 0.77 ACMSD (0.49) CYSLTR2ACMSDKDM4EALDH1A1SMN1; SMN2
SCHEMBL4510789 0.75 CYSLTR2 (0.48) CYSLTR2KDM4EALDH1A1SMN1; SMN2CYSLTR1
SCHEMBL4510787 0.75 CYSLTR2 (0.48) CYSLTR2KDM4EALDH1A1SMN1; SMN2CYSLTR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090143368-A1 Use of Cinnamoyl Compound SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2009-06-04 US disclosed
US-20090143368-A1 Use of Cinnamoyl Compound SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2009-06-04 US disclosed
US-20090143368-A1 Use of Cinnamoyl Compound SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2009-06-04 US disclosed
EP-1857104-A1 USE OF CINNAMOYL COMPOUND Sumitomo Chemical Company, Limited (JP) 2007-11-21 EP disclosed
EP-1857104-A1 USE OF CINNAMOYL COMPOUND Sumitomo Chemical Company, Limited (JP) 2007-11-21 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090143368-A1 Use of Cinnamoyl Compound COL2A1, COL1A1, SMAD2 CYSLTR2 1079/4885ACMSD 2409/4885KDM4E 1537/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.